IMGN News and Press, ImmunoGen Inc. From 09/30/19

Dova Pharmaceuticals (NASDAQ: DOVA ) +39%  on being acquired by Sobi. More news on: Dova Pharmaceuticals, Inc., Bed Bath & Beyond Inc., ImmunoGen, Inc., Stocks on the move, Read more ...

FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, t...

FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients Favorable Tolerability and Differentiated Safety Profile Observed with Mirvetuximab Monotherapy Compared to Chemotherapy Explor...

Sell-side analysts comment on cancer therapy data to be presented at ESMO in Barcelona starting today. More news on: Seattle Genetics, Inc., Clovis Oncology, Inc., AstraZeneca PLC, Healthcare stocks news, Read more ...

Conference Call to be Held at 8 a.m. ET on Monday, September 30 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full data and additional exploratory analyses from the Phase 3 FORWARD ...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) rose last week from 3,260.87 points on Monday (August 5) to settle at 3,294.97 points as of 1:26 p.m. EDT on Friday (August 9). On Wednesday (August 7), Rhythm Pharmaceuticals (NASDAQ: RYTM ) revealed positive results from its Phase 3 clin...

August 6, 2019 Palm Beach, FL –August 6, 2019 – According to an industry report , the global oncology/cancer drugs market (which was valued at $97,401 Million in 2017) is estimated to reach at $176,509 Million by 2025, registering a CAGR of 7.6% from 2018 to 2025....

Immunogen, Inc. (IMGN) Q2 2019 Results Earnings Conference Call August 2, 2019 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Investor Relations and Corporate Communications Mark Enyedy - President and Chief Executive Officer Anna Berkenblit - Chief Medic...

ImmunoGen ( IMGN ) Q2 results : Revenues: $15.5M (+66.7%); Non-cash royalty revenue: $10.4M (+44.4%); License and milestone fees: $5.1M ; R&D support: $0.05M (-87.5%). More news on: ImmunoGen, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

ImmunoGen (NASDAQ: IMGN ): Q2 GAAP EPS of -$0.29 beats by $0.04 . More news on: ImmunoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...